![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 6")
June 02, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
This action places 4-fluoroamphetamine in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, which may impact research involving similar chemical structures to cannabis compounds.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →The DEA placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, meaning these synthetic opioids have no accepted medical use and high abuse potential, potentially impacting differential diagnoses for clinicians.
Read more →The DEA placed N-desethyl isotonitazene and N-piperidinyl etonitazene into Schedule I, impacting clinicians by restricting their use and potentially affecting patient access due to federal control.
Read more →The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinicians and patients encountering these substances.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the US.
Read more →Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.
Read more →Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I
The DEA placed 4-Chloromethcathinone in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, impacting clinicians assessing patient substance use.
Read more →The DEA temporarily placed six synthetic opioids into Schedule I, impacting cannabis clinicians and patients by potentially altering differential diagnoses and requiring awareness of novel psychoactive substance involvement in adverse events.
Read more →Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and clinical research.
Read more →This DEA rule places seven fentanyl-related substances into Schedule I, potentially impacting clinicians evaluating patients with pain who may be considering or currently using these opioids alongside cannabis.
Read more →Digest-Level Clinical Commentary
These scheduling actions reflect the DEA’s primary focus on synthetic opioids, cathinones, benzodiazepines, and designer cannabinoids rather than cannabis itself, which signals a regulatory environment where cannabis medicine practitioners can operate with relative clarity around plant-derived products. The absence of any cannabis rescheduling or prohibition items in this digest underscores that the current scheduling pressure is directed at illicit synthetic compounds that pose acute public health risks, not the cannabinoid therapies we use clinically. As cannabis medicine practitioners, we should recognize that this regulatory attention to novel psychoactive substances actually creates an opportunity to distinguish evidence-based cannabis therapeutics from the synthetic drug landscape, though we must remain vigilant about emerging synthetic cannabinoids that do appear in these schedules.
These regulatory actions reflect the ongoing challenge of synthetic drug proliferation, particularly designer opioids, synthetic cannabinoids, and novel psychoactive substances that are chemically modified to evade existing drug scheduling laws. The recurring placement of structural variants and analogues in Schedule I demonstrates that clandestine manufacturers continue to outpace regulatory frameworks by making minor chemical alterations to create drugs with similar pharmacological effects but technically different legal status. Clinicians should be aware that these substances pose significant public health risks, often with limited safety data and unpredictable potency, and may appear in patients presenting with overdose, acute psychiatric symptoms, or other toxidromes consistent with their drug class.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
- Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
- Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
- Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
